Telegraph Hill Partners
Venture capitalSan Francisco · Growth–Late Stage · 9 people tracked
Team · 9 people
from the firm's websitePublic market activity · per SEC filings
what is this? ⓘDisclosed stake · filed Feb 2016
Disclosed stake · filed Jan 2015
Disclosed stake · filed Feb 2014
7 insider ownership filings (Forms 3/4/5)
Files 13F institutional holdings reports · latest Jan 2016
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- What stage does Telegraph Hill Partners invest at?
- Telegraph Hill Partners invests at the Growth, Late Stage stages.
- What is Telegraph Hill Partners's typical check size?
- Telegraph Hill Partners typically writes checks of $2M – $8M.
- What sectors does Telegraph Hill Partners focus on?
- Telegraph Hill Partners focuses on Biotech, Healthtech, Medical Devices.
- Where is Telegraph Hill Partners located?
- Telegraph Hill Partners is headquartered in San Francisco, US.
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.
EQT Life Sciences is one of Europe's largest and most experienced life sciences investors, focusing on innovative companies developing therapeutics, medical devices, diagnostics, and healthtech globally. The firm has raised approximately 3.5 billion euros across 12 private funds and 3 investment strategies over its 30-year history.
Summit Partners is a growth-focused investment firm with over 41 years of experience investing in category-leading companies across technology, healthcare and life sciences, and growth products and services. The firm leverages a collaborative approach to support market leaders through both minority and majority investments.